Perspective Therapeutics

Perspective Therapeutics OCF Margin

The Operating Cash Flow Margin of Perspective Therapeutics (CATX) as of Oct 22, 2026 is -9,330.77 %. In the previous year, Operating Cash Flow Margin was -1,258.18 % — a change of 641.61% (lower).

OCF Margin

-9,330.77 %

YoY

641.61%

Last updated:

Operating Cash Flow Margin of Perspective Therapeutics is 2025 -9,330.77 % . Operating Cash Flow Margin of Perspective Therapeutics was 2024 -1,258.18 % . It decreases by 641.61% lower compared to the previous year.

The Perspective Therapeutics OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-96.44 USD
Jan 1, 2019
-69.03 USD
Jan 1, 2020
-37.61 USD
Jan 1, 2021
-28.22 USD
Jan 1, 2022
-71.42 USD
Jan 1, 2023
-171.34 USD
Jan 1, 2024
-1,258.18 USD
Jan 1, 2025
-9,330.77 USD
The Perspective Therapeutics OCF Margin history
YEAROCF MarginYoY
-9,330.77 %+641.61%
-1,258.18 %+634.32%
-171.34 %+139.90%
-71.42 %+153.09%
-28.22 %-24.97%
-37.61 %-45.51%
-69.03 %-28.42%
-96.44 %-19.62%
-119.97 %+47.32%
-81.44 %+6.52%
-76.45 %-0.08%
-76.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

Operating Cash Flow Margin of Perspective Therapeutics is -9,330.77 % in 2025.

Operating Cash Flow Margin of Perspective Therapeutics changed from -1,258.18 % to -9,330.77 %, representing a 641.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Perspective Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Perspective Therapeutics

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Perspective Therapeutics